Protocols›Cognitive & neuro›Calm & Sleep
← Protocols
Mitochondrial · MDPsLongevity · experimentalUnlicensed research

Cellular Energy & Longevity

Stack: MOTS-c + Humanin · the mitochondrial-derived peptide side of the longevity category
"A different longevity mechanism from the Epitalon/GHK-Cu foundation: mitochondrial-derived peptides. Exciting biology — MOTS-c behaves like an exercise mimetic in animals — but the honest reality is there are no human trials of giving either peptide. Endogenous levels track with ageing; injecting them is unproven."
GoalMitochondrial function / healthy-ageing (experimental)
Compounds2 · MOTS-c + Humanin
Human evidenceWeak — animal + human association only; no administration trials
StatusUK: unlicensed research chemicals — not controlled, legal to possess, but not approved medicines. No regulator has approved either for any use.
In this stack — snapshot; tap through for the full molecule file
Provenance & evidence layers — of the combination, not the parts
What’s actually established
MOTS-c
A 16-aa mitochondrial-derived peptide; an "exercise mimetic" in mice. In humans, endogenous levels decline with age and associate with muscle and metabolic markers — that’s association, not an administration trial.
Humanin
The first-described mitochondrial-derived peptide; neuroprotective in cell and animal models, with human levels associating with age and cognition. Again association, not administration.
Evidence it adds
Strong mechanism and human association data — but no trials of giving either peptide.
Basis: peer-reviewed preclinical + human observational
The clinically-developed cousin — SS-31
SS-31 / elamipretide
The one mitochondrial peptide with real clinical development. The FDA granted it accelerated approval in Sept 2025 (as Forzinity) — but only for Barth syndrome, an ultra-rare disease, and its broader mitochondrial Phase 3 trials missed their primary endpoints.
What it tells us
That mitochondrial-targeted peptides can clear an approval bar in one specific rare disease — not that they are proven for healthy ageing.
Evidence it adds
None for longevity. A cautionary reference point, not validation.
Basis: FDA accelerated approval (Barth syndrome only)
Grey-market / unsupervised use
Where / who
MOTS-c and Humanin are sold as research peptides, reconstituted for subcutaneous use; any dosing is entirely community-derived.
What changes
No human dosing has been established in trials; product identity, purity and dose are unverified.
Evidence it adds
None — unsupervised use has no trial basis at all here.
Basis: real-world sourcing — not a trial tier
Regulatory — read carefully
MHRA (UK)
Neither MOTS-c nor Humanin is a licensed medicine or a controlled drug — unlicensed research chemicals.
Elsewhere
No FDA/EMA approval for either. (SS-31 is approved only for Barth syndrome.)
What it means
Interesting biology, essentially no human administration evidence — the most speculative protocol here.
Basis: MHRA: unlicensed, not scheduled
Why this pairing

Longevity Foundations covers the telomere / skin / NAD⁺ angle — Epitalon, GHK-Cu, NAD⁺. This pairing is a different mechanism: mitochondrial-derived peptides (MDPs), the small peptides your own mitochondria encode. MOTS-c behaves like an exercise mimetic in animals and its endogenous levels fall with age; Humanin is neuroprotective in models and tracks with cognition. The honest framing, which matters here more than anywhere: the mechanism is genuinely interesting, but no published human trial has given either peptide for ageing or performance. Endogenous association is not proof that injecting them helps.

Members only · the actionable depth
See exactly how it's run
Doses, titration structure and what to monitor are part of membership. The provenance, evidence and status above are always free.
Get the tracker · £4.99/mo →
£4.99/mo · cancel anytime
Cycle shape — how it's typically structured, not a schedule to follow
MOTS-c
SubQ, cyclical (community)
Humanin
SubQ, cyclical (community)
Review
cycle / reassess
Any schedule here is community-derived — there is no trial-established human dosing for either peptide. Included to describe how they’re used in practice, explicitly not a prescription.
What's worth monitoring

The honest caveat dominates: there are no human administration trials, so both efficacy and long-term safety in people are essentially unknown. Reported short-term tolerability from community use is not a safety record, and product identity and purity are unverified. This is the most experimental protocol in the wellness set — a clinician conversation is the floor, and scepticism is warranted. General information, not medical advice.

Evidence
MOTS-c · metabolic / ageing Weak

Exercise-mimetic in mice; human levels decline with age (association). No administration trials.

Humanin · neuroprotection Weak

Neuroprotective in cell/animal models; human association with age and cognition. No administration trials.

SS-31 · context Barth only

Elamipretide is FDA-approved for Barth syndrome (2025); broader mito trials missed endpoints. No ageing evidence.

The honest point

Great mechanism, essentially no human administration evidence. Experimental — not a longevity solution.

Fast facts
Compounds

MOTS-c · Humanin (see also SS-31)

Routes

Subcutaneous (community)

UK strip

GREEN — legal to possess (unlicensed)